PubRank

IFN-β and multiple sclerosis: cross-talking of immune cells and integration of immunoregulatory networks.

PubWeight™: 0.82‹?›

🔗 View Article (PMID 25498525)

Published in Cytokine Growth Factor Rev on November 22, 2014

Authors

Martina Severa1, Fabiana Rizzo2, Elena Giacomini2, Marco Salvetti3, Eliana M Coccia4

Author Affiliations

1: Department of Infectious, Parasitic and Immune-mediated Diseases, Istituto Superiore di Sanità, Rome, Italy. Electronic address: martina.severa@iss.it.
2: Department of Infectious, Parasitic and Immune-mediated Diseases, Istituto Superiore di Sanità, Rome, Italy.
3: Centre for Experimental Neurological Therapies (CENTERS) - Neurology and Department of Neurosciences, Mental Health and Sensory Organs; Sapienza, University of Rome, S. Andrea Hospital Site, Italy.
4: Department of Infectious, Parasitic and Immune-mediated Diseases, Istituto Superiore di Sanità, Rome, Italy. Electronic address: eliana.coccia@iss.it.

Articles citing this ↘

Interferon-β therapy specifically reduces pathogenic memory B cells in multiple sclerosis patients by inducing a FAS-mediated apoptosis. Immunol Cell Biol (2016) 0.76

Drug Efficacy Monitoring in Pharmacotherapy of Multiple Sclerosis with Biological Agents. Ther Drug Monit (2017) 0.76

Allogeneic Adipose-Derived Mesenchymal Stromal Cells Ameliorate Experimental Autoimmune Encephalomyelitis by Regulating Self-Reactive T Cell Responses and Dendritic Cell Function. Stem Cells Int (2017) 0.75

Gene Therapy with Mesenchymal Stem Cells Expressing IFNßAmeliorates Neuroinflammation in Experimental Models of Multiple Sclerosis. Br J Pharmacol (2016) 0.75

The Effects of IFN-β 1a on the Expression of Inflammasomes and Apoptosis-Associated Speck-Like Proteins in Multiple Sclerosis Patients. Mol Neurobiol (2016) 0.75

Articles by these authors ⇆

IFN-β therapy modulates B-cell and monocyte crosstalk via TLR7 in multiple sclerosis patients. Eur J Immunol (2013) 0.78